Innovative drug approvals (half year)

STO-REC-STATWZQGKCT1 Official
38

China · as of 30 Jun 2026

Innovative drug approvals in China (half year) stood at 38 as of 30 June 2026 (State Council).

Original source
Publisher
State Council
Authority tier
T1 Official
Locator
Value of China's innovative drug out-licensing deals hit new high in H1
Retrieved
17 Sep 2026
Status
Verified

What the source says

China approved 38 innovative drugs for marketing during the period, including 31 developed by domestic companies, Tao Qing, head of the bureau for operation, monitoring and coordination with the MIIT, told a media conference.

Verbatim extraction verified: The figure 38 is directly attested in the quoted passage (Value of China's innovative drug out-licensing deals hit new high in H1).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2
MLA
State Council of China. "Value of China's innovative drug out-licensing deals hit new high in H1." 2026, https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2.
Chicago
State Council of China. "Value of China's innovative drug out-licensing deals hit new high in H1." 2026. https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2.
BibTeX
@misc{statecouncil2026innovativehbw2d2, author = {{State Council of China}}, title = {Value of China's innovative drug out-licensing deals hit new high in H1}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2}, note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATWZQGKC T1 Official

Primary Source

Publisher
State Council of China · homepage ↗
Authority tier
Tier 1 · Multilateral Official
Report
Value of China's innovative drug out-licensing deals hit new high in H1
Type
Press release
Published
Locator
Value of China's innovative drug out-licensing deals hit new high in H1
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2